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Impact of RIFLE classiﬁcation in liver
transplantation
Orthotopic liver transplantation (OLT) is a well-
established treatment for patients with advanced
cirrhosis, fulminant acute hepatitis and a
therapeutic option for some malignancies or
metabolic diseases (1). Despite recent advances,
in immunosuppressive regimens, surgical tech-
niques, anesthesia and post-surgical management
of liver transplants, renal dysfunction is a common
complication in these patients (2).
Acute renal failure (ARF) is common in OLT
and associated with several causes including vol-
ume depletion, sepsis and calcineurin inhibitor
toxicity (3, 4). The reported incidence ranges from
12% to 70% (2, 5–7), depending on the criteria
used to deﬁne ARF. In addition, some studies have
shown that acute renal failure is associated with
increased morbidity and mortality (2, 7, 8).
The Acute Dialysis Quality Initiative – ADQI –
workgroup developed a set of criteria for deﬁning
and classifying ARF, i.e., the RIFLE classiﬁcation,
in which ARF is classiﬁed according to the degree of
renal impairment, as Risk of renal dysfunction (R),
Injury to the kidney (I), Failure (F) or Loss (L) of
kidney function and End stage kidney disease (E).
Both L and E criteria were subsequently removed,
remaining only as clinical outcomes (9).
Two studies involving 92 and 300 OLT recipients
have analyzed ARF according to the RIFLE
classiﬁcation and have shown that ARF was
associated with an increase in mortality and length
of hospital stay (10, 11). Several studies on non-
OLT recipients, using RIFLE, have also demon-
strated that ARF is associated with high mortality
and occurrence of chronic kidney disease (12).
This retrospective study was performed in a
large group of OLT recipients submitted to trans-
plantation over the last 15 yr. The main aim of this
study is to evaluate the prognostic value of RIFLE
classiﬁcation in the development of chronic kidney
disease. Furthermore, this study also aims at
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Abstract: Acute renal failure (ARF) is common after orthotopic liver
transplantation (OLT). The aim of this study was to evaluate the prognostic
value of RIFLE classiﬁcation in the development of CKD, hemodialysis
requirement, and mortality. Patients were categorized as risk (R), injury (I)
or failure (F) according to renal function at day 1, 7 and 21. Final renal
function was classiﬁed according to K/DIGO guidelines. We studied 708
OLT recipients, transplanted between September 1992 and March 2007;
mean age 44 ± 12.6 yr, mean follow-up 3.6 yr (28.8% ‡5 yr). Renal
dysfunction before OLT was known in 21.6%. According to the RIFLE
classiﬁcation, ARF occurred in 33.2%: 16.8% were R class, 8.5% I class
and 7.9% F class. CKD developed in 45.6%, with stages 4 or 5d in 11.3%.
Mortality for R, I and F classes were, respectively, 10.9%, 13.3% and
39.3%. Severity of ARF correlated with development of CKD: stage 3 was
associated with all classes of ARF, stages 4 and 5d only with severe ARF.
Hemodialysis requirement (23%) and mortality were only correlated with
the most severe form of ARF (F class). In conclusion, RIFLE classiﬁcation
is a useful tool to stratify the severity of early ARF providing a prognostic
indicator for the risk of CKD occurrence and death.
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This was a retrospective study of 708 OLT recip-
ients transplanted in our unit, between September
1992 and March 2007, using the piggy back
technique, with partial cava clamping.
Clinical data included the age of patients when
the transplantation occurred, their gender, weight,
the etiology of hepatic failure, presence of diabetes
mellitus, hypertension, hepatitis B and C infection,
requirement for acute renal replacement therapy
and immunosuppression. MELD classiﬁcation was
introduced in February 2002, and it has been only
used in clinical practice in Portugal since 2007, and
we did not classify recipients according to this
score.
We analyzed serum creatinine (Scr) values and
the glomerular ﬁltration rate (GFR), estimated by
the Cockcroft–Gault equation, before transplanta-
tion and at days 1, 7, and 21 after transplantation.
Renal dysfunction before transplantation was
deﬁned by GFR £ 60 mL/min or Scr ‡1.5 mg/
dL. At each time point, the patients were catego-
rized as R, I or F according to the RIFLE criteria
(R if increased Scr · 1.5 and/or decreased GFR
>25%; I if doubled Scr and/or decreased GFR
>50%; F if increased Scr · 3 and/or decreased
GFR >75% and/or Scr >4 mg/dL). We selected
the worst value for renal function of these three
time points. The urinary output was not included.
GFR was also calculated after six months,
12 months and yearly thereafter. At the end of
the follow up, renal function was classiﬁed accord-
ing to the K/DIGO Clinical Practice Guidelines, as
chronic kidney disease (CKD) stage 3 if the GFR
was 30–59 mL/min; CKD stage 4 if the GFR was
15–29 mL/min and CKD stage 5 if the GFR
was <15 mL/min or dialysis (13), dependent on
the last value of the GFR.
Biochemical analysis
Laboratorial data considered were Scr at day 1, 7,
21, month 6, month 12 and annually. Biochemical
analysis was performed using standard laboratory
methods.
Immunosuppression protocols
Diﬀerent immunosuppressive protocols have been
used over a period of 15 yr. An association of
cyclosporine, azathioprine and prednisolone was
used in the majority of recipients up to 2003. Since
then, 82% of the recipients received tacrolimus
plus MMF and prednisolone. Between the years
2001 and 2007, sirolimus was used in a limited
number of recipients. The use of cyclosporine,
tacrolimus or sirolimus was considered as a
dichotomous variable (yes or no) Steroids were
usually employed during the ﬁrst months (20 mg/
d), and were slowly decreased during a period up to
12 months. Induction protocols with ATG or
basiliximab were rarely employed until 2007.
Statistical analysis
The data are presented as mean ± SD values for
normally distributed variables or as frequencies for
categorical variables. Independent variables were
compared using the Mann-Whitney or chi-square
tests. Correlations between variables were studied
with the Spearman correlation test for univariate
analysis, and by linear regression for multivariate
analysis (conﬁdence interval of 95%), with forward
method. All tests were performed using the spss
system 15.0 (SPSS Inc., Chicago, IL, USA) and a
p < 0.05 was considered statistically signiﬁcant.
Results
Table 1 shows clinical characteristics of our pop-
ulation. The major cause for OLT was familial
amyloidotic polyneuropathy, Portuguese type, and
alcoholic liver disease. In 31.5% of the cases,
hypertension and diabetes were present before
transplantation. Mean follow up was 3.6 yr (range
1 d to 15 yr), with 28.8% of the patients (n = 204/
708) having more than a ﬁve-yr follow-up period
and 6.5% (n = 46/708) of them with a follow-up
period lasting more than 10 yr.
Table 1. Clinical characteristic of OLT recipients
Variable All patients (n = 708)
Age (yr) 44 ± 12.6
Male gender 64% (453)
Diabetes 15% (106)
Arterial hypertension 16.5% (117)
Etiology
Familial amyloidotic polyneuropathy 30.6% (217)
Alcoholic cirrhosis 20.2% (143)
VHB and VHC cirrhosis 18.2% (129)
Primary biliary cirrhosis 5% (35)
Others 26% (184)
Renal dysfunction pre-transplantation 21.6% (133)
Mean follow-up (yr) 3.6 ± 3.4
( ) Number of patients.
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Table 2 shows the outcome data after the
transplantation. Immunosuppression was based
on calcineurin inhibitors in more than 90% of the
recipients (cyclosporine on 46.4% of the patients
and tacrolimus on 44.7% particularly after 2003).
Only a few of the recipients were treated with
sirolimus in the absence of tacrolimus or cyclo-
sporine. Sirolimus was more frequently used in
recipients with evidence of renal dysfunction pre-
OLT (n = 21/133–15.8% vs. n = 42/575–7.3%
without previous renal dysfunction; p = 0.0013),
and in recipients with evidence of renal lesion
within the ﬁrst 24 h post-OLT (n = 18/63–
28.5%).
In 21.6%of the patients (n = 133 patients), renal
dysfunction was present before OLT, distributed as
follows: 23% were familial amyloidotic poly-
neuropathy patients (n = 31 patients), 18.8% were
alcoholic liver disease patients (n = 25), 18% were
hepatitis patients (n = 24), 10.5% were primary
biliary cirrhosis patients (n = 14), 9%were retrans-
planted patients (n = 12), 5.3% were fulminant
hepatitis patients (n = 7), 3% were cryptogenic
cirrhosis patients (n = 4), 3% were autoimmune
hepatitis patients (n = 4), 3% were primary
sclerosing cholangitis patients (n = 4), 2.3% were
polycystic disease patients (n = 3), 1.5% were
amanita phalloides intoxication patients (n = 2),
0.8% were hemocromatosis patients (n = 1), 0.8%
were Budd Chiari patients (n = 1), and 0.8% were
Wilson disease patients (n = 1).
Renal dysfunction prior to OLT was signiﬁ-
cantly correlated with the development of subse-
quent CKD, stage 3 (r = 0.44, p < 0.0001), stage
4 (r = 0.15, p < 0.0001), stage 5d (r = 0.12, p =
0.003), with dialysis requirement (r = 0.20, p <
0.0001) and with mortality (r = 0.1, p = 0.001).
Hepatorenal syndrome occurred in 14 of these 133
patients (10.5%) and it was also correlated with
mortality (r = 0.1, p = 0.01); eight of these 14
patients died, with a mean follow-up of three wk.
Three patients recovered renal function with no
need for renal replacement therapy, but the others
(three patients) needed dialysis temporarily, even-
tually recovered renal function, within 22 d after
OLT.
According to the RIFLE criteria, 33.2% of the
recipients (n = 235) developed ARF during the
ﬁrst 21 d post-transplant, with a predominance of
the R criteria patients (16.8% of recipients;
n = 119). The mean time for R class development
was 3.8 ± 3.4 d post-OLT. I criteria (8.5%
n = 60) appeared with a mean time of
3.9 ± 3.8 d post-OLT and F criteria (7.9%
n = 56) with a mean time of 2.8 ± 3.5 d post-
OLT. The clinical data of these recipients are
summarized in Table 3. The incidence and degree
of ARF did not correlate with age, gender (except
for a slight predominance of females in the
F subgroup; r = 0.1, p = 0.01) or with the
presence of diabetes. ARF was signiﬁcantly more
frequent in hypertension recipients and less fre-
quent in recipients with familial amyloidotic poly-
neuropathy (p < 0.005). Recipients with viral
cirrhosis did not have an increasing global inci-
dence of ARF, although the R class occurred more
frequently in these patients (R class – 25.5%,
n = 33/129; p = 0.005). Viral hepatitis (r = 0.1,
p = 0.003) particularly VHC cirrhosis (r = 0.1,
p = 0.005) were risk factors for R criteria. Renal
dysfunction pre-OLT was associated with an
increasing incidence of more severe ARF (F class),
but not with the classes I and R. The higher
incidence of ARF (notably the F class) in OLT
recipients under sirolimus probably only represents
a more frequent use in recipients with initial
evidence of increasing renal risk (renal dysfunction
pre-OLT and changes in renal function in the ﬁrst
24 h), as previously indicated.
Concerning the primary end-point of this study,
RIFLE classiﬁcation was a good predictor of CKD
development at the end of the follow up. In fact,
55.5% (n = 66/119) of the recipients stratiﬁed to
R class in the ﬁrst 21 d post-transplant developed
CKD (stage 3 in 43.7% of the patients, stage 4 in
8.4% and stage 5d in 3.4%) while 80% (n = 48/
60) of the recipients classiﬁed as I class developed
this same condition (stage 3 in 65% of the patients,
stage 4 in 8.3% and stage 5d in 6.7%). The highest
incidence of CKD (92.8%, n = 52/56) was found
in the F class (57.1% developed CKD stage 3, and
12.5% stage 4; 23.2% of patients that developed F
criteria were on regular hemodialysis at the time
of the last follow-up). In both univariate and
Table 2. Outcome data post-transplantation
Variable All patients (n = 708)
Acute renal failure (RIFLE criteria) 33.2% (235)
Renal replacement therapy 10.3% (73)
Retransplantation 12.6% (89)
Immunosuppression
With cyclosporine 46.4% (329)
With tacrolimus 44.7% (316)
With sirolimus 8.9% (63)
Development of chronic kidney disease 45,6% (323)
Stage 3 34.3% (243)
Stage 4 6.2% (44)
Stage 5d 5.1% (36)
Months to CKD (‡stage 3) 14.1 ± 21.7
Months to CKD stage 5d 14.1 ± 23.6
Mortality 21.8% (154)
( ) Number of patients.
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multivariate analysis, ARF was correlated with
development of all stages of CKD, the R and I
criteria were correlated with the development of
CKD stage 3 (p = 0.02 and p < 0.001, respec-
tively), but not with the others stages of CKD, and
F class was correlated with CKD stage 3, stage 4
and 5d (p < 0.04).
According to KDIGO deﬁnitions, 45.6%
(n = 323) of all recipients developed CKD stages
3 to 5d, with 11.3% of them attaining stage 4 or 5d.
Stage 3 (34.3% of all OLT recipients, n = 243) was
diagnosed at a mean of 11.4 ± 17.1 month post-
transplantation, stage 4 (6.2% of OLT recipients,
n = 44) at 22.3 ± 27.7 month, and stage 5d (5.1%
of OLT recipients, n = 36) at a mean of
14.1 ± 26.3 month (Table 2). CKD was common
even in patients without ARF, with 7.9% (n = 37/
473) of recipients developing stage 4 or 5d, and an
additional 25.4% (n = 120/473) developing stage
3. In the subgroup of the 204 OLT recipients who
survived for more than ﬁve yr, 51.2% (n = 106/
204) of them developed CKD stage 3 to 5d, with
9.8% (n = 20/204) presenting advanced CKD
(stage 4 or 5d). If we further extend the analysis to
the 46 recipients who were followed up for a period
of 10 ormore years, only 30.4%of themwill have no
evidence of CKD (n = 14/46), while stage 3 will be
observed in 56.6% (n = 26/46), and stage 4 or 5 in
13% (n = 6/46) Incidence of CKD was higher in
recipients with evidence of ARF (Table 3), and the
degree of ARFwas correlated with the development
of all stages of CKD (p < 0.01). This incidence of
CKD progressively increased along with the degree
of acute renal failure, with 35.7% (n = 20/56) of
recipients included in the F class developing CKD
stage 4 or 5d during the study period, and the
majority of the remaining recipients developing
CKD stage 3. According to multivariate analysis,
risk factors for CKD development were age, renal
dysfunction prior to OLT, ARF, F class, and
hemodialysis requirement. There was no impact
on CKD development whenever CNI were or not
used, probably due to the fact that almost all
patients were under CNI. If we analyzed CKD
according to the GFR, we ﬁnd that permanent renal
dysfunction, GFR < 45mL/min, was, on univari-
ate analysis, positively correlated with the use of
Azathioprine (r = 0.13; p = 0.001), CyA (r =
0.12; p = 0.003) and sirolimus (r = 0.16; p <
0.001) and was inversely correlated with the use of
tacrolimus (r = )0.12; p = 0.002) and MMF
(r = )0.16; p < 0.001). On multivariate analysis,
permanent renal dysfunction was positively corre-
lated with sirolimus (CI 0.05 to 0.31; p = 0.008)
Table 3. Clinical characteristic of OLT recipients with ARF according to the RIFLE classification compared with patients without ARF
Variables Patients without ARF (n = 473)
Patients with ARF
R (n = 119) I (n = 60) F (n = 56) Total (n = 235)
Age (yr) 43.6 ± 12.4 45.9 ± 13 45.5 ± 13 41.7 ± 12.8 44.8 ± 13
Male gender 65.8% (311) 65.5% (78) 61.7% (37) 48.2% (27)-* 60.4% (142)
Diabetes 14% (66) 21.4% (25) 17.2% (10) 10% (5) 17% (40)
Arterial HT 15% (71) 21.4% (25) 22.4% (13) 15.7% (8) 19.6% (46)**
Etiology
FAP 34.2% (162)** 21.8% (26) 25% (15) 25% (14) 23.4% (55)
Alcoholic cirrhosis 18.2% (86) 23.5% (28) 28.3% (17) 21.4% (12) 24.2% (57)
HBV/HCV cirrhosis 16.7% (79) 27.7% (33)** 16.7% (10) 12.5% (7) 21.3% (50)*
PBC 4.7% (22) 2.5% (3) 10% (6) 7.3% (4) 5.5% (13)
RD pre-OLT 17.8% (84) 20.2% (24) 11.7% (7) 32.7% (18)* 20.9% (49)
ARF 0% 16.8% 8.5% 7.9% 33.2%
RRT 5.5% (26) 6.7% (8) 10% (6) 58.9% (33)** 20% (47)**
CKD development
Stage 3 25.4% (120) 43.7% (52)* 65% (39)** 57.1% (32)** 52.4% (123)**
Stage 4 4.7% (22) 8.4% (10) 8.3% (5) 12.5% (7)* 9.4% (22)*
Stage 5d 3.2% (15) 3.4% (4) 6.7% (4) 23.2% (13)** 8.9% (21)**
Total 33.3% 55.5%* 80%** 92.8%** 70.6%
ISS
With cyclosporine 46.5% (220) 48.8% (58) 50% (30) 37.5% (21) 46.4% (109)
With tacrolimus 45.9% (217) 44.5% (53) 35% (21) 44.6% (25) 42.1% (99)
With sirolimus 7.6% (36) 6.7% (8) 15% (9) 17.9% (10) 11.5% (27)**
Retransplantation 12.3% (58) 10.9% (13) 11.7% (7) 19.6% (11) 13.2% (31)
Mortality 23.5% (111) 10.9% (13)-** 13.3% (8) 39.3% (22)** 18.3% (43)
(-) inverse correlation; *p < 0.05; **p < 0.005.
() Number of patients; arterial HT, arterial hypertension; FAP, familial amyloidotic polyneuropathy; RD pre-OLT, renal dysfunction pre-orthotopic liver transplantation; ARF,
acute renal failure; RRT, renal replacement therapy; ISS, immunosuppression.
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and inversely correlated with the use of MMF (CI
)0.2 to )0.07; p < 0.001).
Concerning the secondary aim of this study, renal
replacement therapy was required for 73 recipients
(10.3%), 37 patients required it only temporarily,
and it was correlated in both uni- and multivariate
analysis with ARF (r = 0.21, p < 0.0001; p <
0.001). Dialysis was required for 6.8% of R class
patients, for 10.2% of I class patients and for 62.3%
of F class patients (p < 0.0001). The mortality for
the three groups R, I and F was, respectively,
10.9%, 13.3% and 39.3% versus 23.5% in OLT
recipients without ARF. Mortality was higher in F
class, in both univariate and multivariate analysis
(r = 0.12, p = 0.001 and CI 0.06 to 0.28,
b = 0.11, p = 0.003, respectively). The R criteria
was inversely correlated with mortality (r = )0.12,
p = 0.002 and CI )0.2 to )0.03, b )0.1, =0.006).
Results on survival estimates using Kaplan–Meier
formulation are presented in Fig. 1. As expected,
there was a statistically decreased survival in F class
patients.
Discussion
Changes in renal function are common after liver
transplantation, both at an early stage with
appearance of ARF, and latter with development
of CKD. In our study of 708 OLT recipients both
these observations are clearly demonstrated, but
we further show that the presence of ARF (iden-
tiﬁed in 33.2% of recipients), and particularly the
severity of early ARF (deﬁned by standardized
criteria) are associated with the development of
CKD in the long term, allowing a very early
identiﬁcation of patients at risk.
Using RIFLE classiﬁcation, the majority of ARF
cases are classiﬁed as R class, followed by I class
and F class. ARF of any severity (criteria R, I and
F) correlated with subsequent development of
chronic renal disease with GFR < 60 mL/min
(CKD stage 3 or higher), while F class, the worst
in terms of severity, was also associated with the
appearance of CKD stage 4 and 5d and an
increased mortality rate. The presence of mild to
moderate ARF (R and I criteria) was not associated
with an increased mortality or with the develop-
ment of advanced renal failure, at least over the
follow-up period. Interestingly, recipients with R
class presented in fact a signiﬁcantly lower mortal-
ity when compared to recipients without ARF.
Both the R group and those without ARF have a
similar follow-up procedure (data not shown), and
except for a higher percentage of recipients with
viral hepatitis and lower proportion of recipients
with familial amyloidotic polyneuropathy, there are
no apparent diﬀerences between the two groups, for
which we have no explanation at the moment.
However, we did not study the causes of mortality.
Future studies are needed to clarify risk factors for
ARF. The identiﬁcation of these risk factors may
lead to a development of measures to decrease ARF
after OLT, and consequently reduce the severity of
renal injury (F class), thus decreasing the develop-
ment of CKD and mortality.
It is important to note that renal dysfunction
pre-OLT was only correlated with the F criteria
(failure) and was not correlated with less severe

































   Failure 
   Risk
   Injury
  no AKI
Fig. 1. Kaplan–Meier survival for OLT
recipients according to RIFLE
classiﬁcation (failure, injury, risk and
no ARF lesion); p = 0.0002. There is a
signiﬁcant diﬀerence between Failure
and no AKI lesion.
Ferreira et al.
398
degrees of ARF (R and I criteria) In addition,
F class was associated with dialysis requirement
and with a higher mortality. We may argue the fact
that patients with renal dysfunction pre-OLT may
be more susceptible to renal insult with severe
complications, as renal failure, development of
chronic renal disease and higher mortality.
The higher mortality in this group of patients is
in agreement with the ﬁndings of previous studies
(14, 15).
Ultimately advanced CKD, stages 4 and 5d,
developed in 11.3% of recipients, with 5.1% devel-
oping end stage renal disease (stage 5d). Less severe
degrees of renal failure (stage 3) developed in 34.3%
of all recipients, a ﬁgure that increases to 42.2% in
patients followed for a period of more than ﬁve yr,
when 9.8% of surviving recipients will have
advanced renal failure (stage 4 or 5d). After a
10-yr follow-up period, only 30.4% of surviving
recipients will not have evidence of CKD, and 13%
will have advanced CKD (stage 4 or 5d). Although
the incidence of advanced CKD in our study is
similar to that previously described, the incidence of
lesser degrees of CKD (stage 3) according to the K/
DIGO deﬁnitions have only recently been described
in detail (16). In our study the incidence of stage 3 is
very high, ranging from 34.3%, in the entire cohort,
to 42.2% in those with a follow-up period of more
than ﬁve yr, and 56.6% for those followed for 10 or
more years. The recent report found an incidence of
CKD stage 3 of 47% in stable recipients with a
follow-up period of at least ﬁve yr (16). Also CKD
post-OLT is probably progressive once stage 3 has
been attained. Taken together, these results dem-
onstrate that in the next few years the proportion of
OLT patients presenting with advanced renal dis-
ease will continue to increase, resulting in consid-
erable morbidity and mortality.
There are some limitations to our study. First of
all, it is a retrospective study with all the limita-
tions of such studies, including a time span of
15 yr, a period during which recipients recruitment
and clinical protocols were undoubtedly subjected
to various changes. The immunosuppression strat-
egy was based on cyclosporine in early years, and
based on tacrolimus after 2003. We noticed no
inﬂuence of the type of calcineurin inhibitor used
on the appearance of ARF. Tacrolimus and MMF
may have a protective eﬀect on renal dysfunction,
although this apparent beneﬁt may only result
from the shorter follow-up of patients treated with
these two immunosuppressants. Sirolimus was
more frequently used in recipients with early
evidence of renal dysfunction (either prior to or
immediately after OLT) and also with more
frequent evidence of severe ARF. However, a
delayed recovery of renal function, like the one
described in renal allografts with acute tubular
necrosis, cannot be excluded (17).
Secondly, the number of FAP patients is very
high and not comparable to the majority of liver
centers. Nevertheless, our FAP patients, according
to the RIFLE criteria, had less ARF events
(p < 0.005) than the others and, according to the
K/DIGO deﬁnition, had less renal dysfunction
prior to OLT (p = 0.01) and had less CKD when
compared to the others patients (p < 0.0001). We
analyzed the data excluding FAP patients and the
results were very similar to those presented in the
manuscript and, therefore, FAP patients dont
represent any bias to the results.
Thirdly, the recipients selection was not based
on the MELD score. In fact the MELD score was
introduced only after 2002 and in Portugal only
after 2007, and our study period goes back to 1992.
A retrospective scoring would be inaccurate,
therefore we did not attempt it, as we were not
studying the causes of ARF, but instead the
prognostic importance of its presence and degree.
Fourthly, changes in renal function (pre- and
post-OLT) were based on Scr values, a further
limitation, as malnutrition, reduced muscular mass
and lack of hepatic function may contribute for
false lower Scr levels (2). However, we believe that
by estimating GFR on the basis of age, weight and
creatinine we can partially surpass such limitation.
Nevertheless, we cannot exclude that the number
of patients with previous renal dysfunction may
have been underestimated. Despite this limitation,
recipients with renal dysfunction pre-OLT had
severe ARF more frequently (and not class R or I),
indicating the reliability of our approach. Not-
withstanding, an estimation of GFR was applied to
all patients.
Finally, we did not use urine output to stratify
ARF. This approach has been validated by others
(12), and we decided to take this approach as
reliable records from the earlier recipients were
unavailable and diuretics were used.
Altogether our results indicate that in the early
post-transplant period, aggressive clinical care must
be employed to prevent the development of severe
ARF (F criteria), as soon as the ﬁrst evidence of
renal lesion appears. Thepresence ofmild changes in
renal function within the ﬁrst days after the trans-
plant (i.e., the R criteria) may rapidly progress to
severe ARF, with considerable morbidity and mor-
tality, as we have shown. However, our data also
indicate that in the long term, if the ARF does not
progress,mortality does not increase (in fact is lower
than the control group), although increased inci-
dence of CKD will be present, particularly stage 3.
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Conclusions
In conclusion, RIFLE classiﬁcation is a simple and
a useful tool to stratify the severity of ARF
providing a valuable prognostic indicator of the
risk of developing chronic renal dysfunction and
death. The R and I criteria predict in the long term
a GFR < 60 mL/min, and the F criteria is a
strong predictor of mortality and advanced CKD.
As a consequence of our study, it is clear that the
presence of early degrees of acute kidney injury
(criteria R and I) require aggressive treatment as
they anticipate the appearance of F criteria and in
the long term they are associated with moderate
CKD. By employing such strategy, taking every
eﬀort not to allow progression of the early acute
renal lesion, we may be able in the long term to
reverse the increased incidence of chronic renal
failure and improve the survival rate of OLT
recipients.
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